Board of Directors
Mr. Gladney served as President and Chief Executive Officer for the company from November 2015 to April 2019. He remains as Chairman of the Board of Directors, a position held since October 2016. Mr. Gladney joined the Company in November 2015 as President-elect and a member of the board of directors. Prior to joining the Company, Mr. Gladney served as Chairman and Chief Executive Officer of Lanx, Inc., a medical device company focused on developing and commercializing innovative devices for spinal surgery. Prior to joining Lanx, Inc., Mr. Gladney was a Healthcare Operating Partner at Norwest Equity Partners (NEP), where he was responsible for strategic planning, business growth, and corporate governance for NEP portfolio companies, and executing new investment opportunities for the firm. Prior to joining NEP, Mr. Gladney served as President and Chief Executive Officer of several medical device companies including Heart Leaflet Technologies and ACIST Medical Systems, both of which were acquired by The Bracco Group. He also served as Chairman, Chief Executive Officer and President of Complex Technologies, a publicly traded orthopedic and health and wellness electro therapy company. Mr. Gladney currently serves on the Board of Directors of ARIA CV, Inc. and has been a member of a number of other private and public company boards. After the sale of Lanx, Inc., he acted as a private investor and small business consultant.
Mr. Bandy is the President and Chief Executive Officer of ReShape Lifesciences Inc. Mr. Bandy has extensive leadership experience in health care and specifically in the obesity and bariatric space. Most recently, Mr. Bandy was President and Chief Executive Officer of BroadSpot Imaging Corporation, a developer of medical devices for eye care, since April 2017. From April 2013 to August 2013, Mr. Bandy was President of the Wellness division at Alphaeon Corporation, where he was responsible for business development, commercial activities, strategy and acquisition integration. He previously spent 10 years at Inamed and Allergan leading their Health divisions, through the acquisition by Allergan.
Mr. Blackford has served a director since August 2016. Mr. Blackford has over 30 years of executive experience in the healthcare industry, having most recently served as President, Chief Executive Officer, and member of the Board of Directors of Universal Hospital Services Inc., a nationwide provider of medical equipment management, technology, and service solutions for the healthcare industry. From 2001 to 2002, Mr. Blackford was Chief Executive Officer of Curative Health Services, Inc., a specialty healthcare services and pharmacy distribution company. Mr. Blackford has also served in executive roles at pharmacy benefit management companies, including Medintell Systems Corporation, and ValueRx (acquired by Express Scripts). He currently serves as a member of the Board of Directors for Wright Medical Group N.V., Halyard Health, Inc., and PipelineRx.
Ms. McDougal has served as a director since July 2015. With more than 18 years of experience in the healthcare industry at an executive level, she has also served as Executive Vice President at Optum, Inc., part of UnitedHealth Group, Inc. Prior to her time at Optum, she served as Chief Executive Officer of UnitedHealth Group’s subsidiary UnitedHealth Military & Veterans Services, LLC, and previously served as Chief Operating Officer of UnitedHealth Military & Veterans Services. Before joining UnitedHealth Military & Veterans Services, she served as a Vice President of UnitedHealthcare Medicare & Retirement. Additionally, she served as President of UnitedHealth International, and Vice President of OptumInsight.
Arda M. Minocherhomjee, Ph.D., was a founding Partner of Chicago Growth Partners. Prior to founding CGP, Dr. Minocherhomjee was a Managing Director at William Blair Capital Partners and a Managing Director and member of the Board of Managers of WBCP VI and VII. Prior to that, Dr. Minocherhomjee was a Senior Healthcare Analyst and partner at William Blair & Company. As head of the firm’s Healthcare Research Group, Dr. Minocherhomjee covered several sectors, including drugs/drug delivery, medical devices and selected healthcare services. He was a Wall Street Journal “All-Star Analyst” in both medical device and pharmaceutical sectors. Select current and past directorships include: AtheroGenics, CryoCor, DJ Pharma, EndoGastric Solutions, Favrille, Genoptix, Morton Grove Pharmaceuticals, NuVasive, PharmaResearch Corporation, POINT Biomedical, Proteome and TargeGen. Dr. Minocherhomjee received a M.S. (Pharmacology) from the University of Toronto, a Ph.D. and a MBA from the University of British Columbia.